Brainstorm Cell Therapeutics | BCLI - Operating Expenses


Brainstorm Cell Therapeutics reported $2.05M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
Biogen USD 2.98B 1.02B Jun/2026
Brainstorm Cell Therapeutics USD 2.05M 198K Mar/2026
Cipla INR 62.31B 3.04B Jun/2026
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.19M 96K Mar/2026
CSL USD 5.7B 2.82B Dec/2025
Cytokinetics USD 207.8M 7.22M Jun/2026
Gilead Sciences USD 3.95B 19.57B Jun/2026
Grifols EUR 1.99B 217.4M Dec/2025
Halozyme Therapeutics USD 193.34M 1.15M Jun/2026
Mesoblast USD 82.31M 26.16M Dec/2025